微创医疗连续四年亏损股东高瓴资本注资救援

经济参考报04-24

港股上市公司微创医疗近日发布2023年财报显示，微创医疗持续亏损四年，公司持续经营能力存在重大不确定性。在债务高悬的情况下，第四大股东高瓴资本注资2亿美元融资和3亿美元借款相助。　　微创医疗是我国一家创新型医疗器械集团，覆盖心血管及结构性心脏病等领域。高瓴资本是亚洲规模最大私募之一，管理的基金规模超730亿美元。2020年高瓴资本耗资6.45亿港元增持微创医疗股，此后更是直接入股了多家微创系子公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429149806?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-24 02:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429149806","market":"hk","top_or_hot":-1,"title":"微创医疗连续四年亏损 股东高瓴资本注资救援","media":"经济参考报","content":"<div>\n<p>港股上市公司微创医疗近日发布2023年财报显示，微创医疗持续亏损四年，公司持续经营能力存在重大不确定性。在债务高悬的情况下，第四大股东高瓴资本注资2亿美元融资和3亿美元借款相助。　　微创医疗是我国一家创新型医疗器械集团，覆盖心血管及结构性心脏病等领域。高瓴资本是亚洲规模最大私募之一，管理的基金规模超730亿美元。2020年高瓴资本耗资6.45亿港元增持微创医疗股，此后更是直接入股了多家微创系子公司...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202404243056379391.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微创医疗连续四年亏损 股东高瓴资本注资救援</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微创医疗连续四年亏损 股东高瓴资本注资救援\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 02:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202404243056379391.html><strong>经济参考报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>港股上市公司微创医疗近日发布2023年财报显示，微创医疗持续亏损四年，公司持续经营能力存在重大不确定性。在债务高悬的情况下，第四大股东高瓴资本注资2亿美元融资和3亿美元借款相助。　　微创医疗是我国一家创新型医疗器械集团，覆盖心血管及结构性心脏病等领域。高瓴资本是亚洲规模最大私募之一，管理的基金规模超730亿美元。2020年高瓴资本耗资6.45亿港元增持微创医疗股，此后更是直接入股了多家微创系子公司...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202404243056379391.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0594300419.USD","symbol_name":"富达中国消费基金A","start_time":0,"source_url":"http://finance.eastmoney.com/a/202404243056379391.html","article_id":"2429149806","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404243056379391.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2429149806","pubTimestamp":1713895956,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"港股上市公司微创医疗近日发布2023年财报显示，微创医疗持续亏损四年，公司持续经营能力存在重大不确定性。在债务高悬的情况下，第四大股东高瓴资本注资2亿美元融资和3亿美元借款相助。微创医疗是我国一家创新型医疗器械集团，覆盖心血管及结构性心脏病等领域。高瓴资本是亚洲规模最大私募之一，管理的基金规模超730亿美元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"89618":"京东集团-SWR","LU0594300419.USD":"富达中国消费基金A","LU0051755006.USD":"摩根大通中国A (dist)","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","JD":"京东","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0865486749.SGD":"Eastspring Investments - Asian Equity Income AS SGD-H","LU0868486357.SGD":"JPMorgan Funds - Emerging Markets Opportunities A (acc) SGD-H","LU0359201612.USD":"贝莱德中国基金A2","BK1610":"ETF&股票定投概念","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1044875133.USD":"天利亚洲反向股票 AU Acc","00853":"微创医疗","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU0048580855.USD":"富达大中华区A","BK1591":"就地过年概念","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","09618":"京东集团-SW","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1142":"互联网与直销零售","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0228659784.USD":"施罗德金砖四国基金","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","BK1575":"同股不同权","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1100":"医疗保健设备","LU0128522157.USD":"TEMPLETON ASIAN GROWTH \"A\" ACC","BK1588":"回港中概股","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0084288322.USD":"Natixis Asia Equity RD USD","LU0488056044.USD":"Allianz Asian Multi Income Plus Cl AM DIS USD","BK1583":"高瓴概念","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD"},"translate_title":"Minimally Invasive Medical has lost money for four consecutive years, shareholder Hillhouse Capital injected capital to rescue","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89618":0.6,"09618":1,"00853":1,"JD":0.6},"content_text":"港股上市公司微创医疗近日发布2023年财报显示，微创医疗持续亏损四年，公司持续经营能力存在重大不确定性。在债务高悬的情况下，第四大股东高瓴资本注资2亿美元融资和3亿美元借款相助。　　微创医疗是我国一家创新型医疗器械集团，覆盖心血管及结构性心脏病等领域。高瓴资本是亚洲规模最大私募之一，管理的基金规模超730亿美元。2020年高瓴资本耗资6.45亿港元增持微创医疗股，此后更是直接入股了多家微创系子公司。截至2023年6月末，高瓴资本通过旗下子公司对微创医疗直接持股8.38%，为其第四大股东。　　近年来，微创医疗持续亏损，相较于2021年6月的市值历史高峰1275.07亿港元，目前市值约101亿港元。微创医疗2023年财报显示，2023年微创医疗公司实现营收9.51亿美元，归母净利润亏损4.78亿美元。微创医疗的业绩从2020年出现亏损，此后一蹶不振。2020年至2022年间，微创医疗分别亏损2.23亿美元、3.51亿美元、5.88亿美元。　　微创公司认为亏损原因由于新冠疫情和冠脉支架集采导致。微创医疗2020年半年报显示，受疫情影响，微创医疗上半年净利润亏损6876万美元。2020年下半年，国家高值医用耗材冠脉支架集中带量采购让微创医疗核心板块心血管介入业务受到重大影响。比如，心脏支架价格从均价1.3万元人民币下降至700元人民币左右。　　2023年财报显示，微创医疗还存在严重的财务问题。2024年微创医疗必须偿还总计7.43亿美元的两笔债务，其中4.48亿美元6月到期。4月5日，微创医疗发布公告称，公司自高瓴资本等机构处取得了一笔融资和借款，以偿还即将到期的可转债。至此，微创医疗的债务风波得以暂时平息。　　尽管股东高瓴资本愿意出手相救，但这并非是一场无条件的“输血”。据双方协议，微创医疗必须承诺在2024年前亏损不超过2.75亿美元，2025年中亏损不超过1亿美元，2025年底亏损不超过5500万美元，2026年中盈利不少于4500万美元，2026年底盈利不少于9000万美元。这意味着微创医疗需要在2024年减亏56%，2025年要在此基础上再次大幅减亏80%。如果未能达到，债权人有权要求微创提前偿还5000万美元贷款，并支付利息等等。　　公司最终能否成功走出亏损的困境，还需要微创医疗自身的努力和市场的验证。记者致电微创医疗，但截至记者发稿前未得到回复。（文章来源：经济参考报）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429149806"}

微创医疗连续四年亏损 股东高瓴资本注资救援

精彩评论

微创医疗连续四年亏损股东高瓴资本注资救援